• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

    12/11/20 8:00:00 AM ET
    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XOMA alert in real time by email

    SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy.

    “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. “I look forward to benefiting from Natasha’s extensive experience and acumen as we oversee the next stages of Alpine’s growth to the benefit of Alpiners, shareholders and patients alike.”

    Ms. Hernday currently serves as Executive Vice President, Corporate Development and as a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc. (NASDAQ: SGEN). Since joining Seagen in 2011, Ms. Hernday has built and led the business development team responsible for licensing deals, acquisitions and strategic alliances. From 1994 through 2010, after starting her career in molecular and mammalian cell biology, Ms. Hernday served in various roles of increasing responsibility at Amgen Inc., including as Director, Mergers & Acquisitions and as Director, Out-Partnering. She also serves on the board of directors of Xoma Corp. (NASDAQ: XOMA) and PDL BioPharma, Inc. (NASDAQ: PDLI), and on the Knight Campus External Advisory Board for the University of Oregon.

    Ms. Hernday received her BA in microbiology from the University of California at Santa Barbara and MBA from Pepperdine University.

    Concurrent with Ms. Hernday joining Alpine’s Board of Directors, the company also announced that Paul Sekhri will be stepping down as a director of the company. Mr. Sekhri has served on Alpine’s Board of Directors since February 2016.

    Mitchell H. Gold commented, “On behalf of the Board and Alpine’s executive team, I would like to thank Paul for the service he has provided to the company and wish him well in any and all future endeavors.”

    About Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is creating multifunctional immunotherapies via unique protein engineering technologies designed to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, the future development plans and commercial potential of our product candidates, the progress and potential of our other ongoing development programs, and our ability to successfully develop and achieve milestones in our development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    “Secreted Immunomodulatory Proteins”, “SIP”, “Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,” “vIgD” and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

    Get the next $XOMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XOMA
    $PDLI
    $ALPN
    $SGEN

    CompanyDatePrice TargetRatingAnalyst
    XOMA Royalty Corporation
    $XOMA
    4/17/2025$35.00Buy
    The Benchmark Company
    XOMA Royalty Corporation
    $XOMA
    4/29/2024$40.00Outperform
    Leerink Partners
    Alpine Immune Sciences Inc.
    $ALPN
    4/9/2024$55.00Buy
    Guggenheim
    Alpine Immune Sciences Inc.
    $ALPN
    2/15/2024$44.00Outperform
    Wolfe Research
    Alpine Immune Sciences Inc.
    $ALPN
    10/18/2023$18.00Buy
    Berenberg
    Alpine Immune Sciences Inc.
    $ALPN
    10/17/2023$18.00Buy
    Berenberg
    Alpine Immune Sciences Inc.
    $ALPN
    10/5/2023$19.00Outperform
    RBC Capital Mkts
    Alpine Immune Sciences Inc.
    $ALPN
    6/26/2023$14.00Outperform
    Oppenheimer
    More analyst ratings

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/9/25 4:44:30 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/7/25 4:39:59 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $19,980 worth of shares (1,000 units at $19.98) and bought $6,221 worth of Depositary Shares - 8.375% Series B Perpetual Preferred (245 units at $25.39), decreasing direct ownership by 71% to 3,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/2/25 4:30:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Financials

    Live finance-specific insights

    See more
    • XOMA Royalty Completes Sale of Kinnate Pipeline Assets

      XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024.

      4/14/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.  Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respe

      3/20/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about January 15, 2025, to respective holders

      12/19/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    SEC Filings

    See more
    • SEC Form DEF 14A filed by XOMA Royalty Corporation

      DEF 14A - XOMA Royalty Corp (0000791908) (Filer)

      4/15/25 4:30:48 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by XOMA Royalty Corporation

      PRE 14A - XOMA Royalty Corp (0000791908) (Filer)

      4/4/25 4:30:37 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by XOMA Royalty Corporation

      10-K - XOMA Royalty Corp (0000791908) (Filer)

      3/17/25 4:45:58 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/9/25 4:44:30 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/7/25 4:39:59 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $19,980 worth of shares (1,000 units at $19.98) and bought $6,221 worth of Depositary Shares - 8.375% Series B Perpetual Preferred (245 units at $25.39), decreasing direct ownership by 71% to 3,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/2/25 4:30:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Leadership Updates

    Live Leadership Updates

    See more

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

      Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

      5/9/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

      EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025. Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET.  Mr. Hughes will join the "Pros and Cons of Royalty Model – Especially in Current Financing Environment" panel discussion at 4:00 PM ET.  Mr. Sitko will participate in the "Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?" panel at 5:00 PM ET.  

      5/7/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance
    • XOMA Royalty Completes Sale of Kinnate Pipeline Assets

      XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024.

      4/14/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 4:49:22 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 10:21:59 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      4/30/24 4:20:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    $PDLI
    $ALPN
    $SGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

      The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

      4/17/25 8:34:06 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on XOMA with a new price target

      Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00

      4/29/24 8:01:47 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Alpine Immune Sciences with a new price target

      Guggenheim initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $55.00

      4/9/24 7:38:17 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care